CL2020001244A1 - Inhibidores de inmunoproteasoma. - Google Patents

Inhibidores de inmunoproteasoma.

Info

Publication number
CL2020001244A1
CL2020001244A1 CL2020001244A CL2020001244A CL2020001244A1 CL 2020001244 A1 CL2020001244 A1 CL 2020001244A1 CL 2020001244 A CL2020001244 A CL 2020001244A CL 2020001244 A CL2020001244 A CL 2020001244A CL 2020001244 A1 CL2020001244 A1 CL 2020001244A1
Authority
CL
Chile
Prior art keywords
compounds
description
inhibitors
immunoproteasome inhibitors
immunoproteasome
Prior art date
Application number
CL2020001244A
Other languages
English (en)
Inventor
Yan Lou
Timothy Duncan Owens
Kenneth Albert Brameld
David Michael Goldstein
Original Assignee
Principia Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Principia Biopharma Inc filed Critical Principia Biopharma Inc
Publication of CL2020001244A1 publication Critical patent/CL2020001244A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

EN LA PRESENTE DESCRIPCIÓN SE PROPORCIONAN COMPUESTOS, TALES COMO UN COMPUESTO DE LA FÓRMULA (I), O UNA SAL FARMACÉUTICAMENTE ACEPTABLE DE ESTE, QUE SON INHIBIDORES DE INMUNOPROTEASOMA (TALES COMO LMP2 Y LMP7). LOS COMPUESTOS DESCRITOS EN LA PRESENTE DESCRIPCIÓN PUEDEN SER ÚTILES PARA EL TRATAMIENTO DE ENFERMEDADES TRATABLES MEDIANTE LA INHIBICIÓN DE INMUNOPROTEASOMAS. EN LA PRESENTE DESCRIPCIÓN TAMBIÉN SE PROPORCIONAN COMPOSICIONES FARMACÉUTICAS QUE CONTIENEN TALES COMPUESTOS Y PROCESOS PARA PREPARAR TALES COMPUESTOS.
CL2020001244A 2017-11-16 2020-05-12 Inhibidores de inmunoproteasoma. CL2020001244A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762587376P 2017-11-16 2017-11-16

Publications (1)

Publication Number Publication Date
CL2020001244A1 true CL2020001244A1 (es) 2020-08-21

Family

ID=64746633

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2020001244A CL2020001244A1 (es) 2017-11-16 2020-05-12 Inhibidores de inmunoproteasoma.

Country Status (18)

Country Link
US (2) US11225493B2 (es)
EP (1) EP3710458A1 (es)
JP (1) JP7277457B2 (es)
KR (1) KR102625984B1 (es)
CN (1) CN111491938B (es)
AU (1) AU2018367515B2 (es)
CA (1) CA3080949C (es)
CL (1) CL2020001244A1 (es)
CO (1) CO2020007150A2 (es)
EA (1) EA202090900A1 (es)
IL (1) IL274523B2 (es)
MA (1) MA50906A (es)
MX (2) MX2020005046A (es)
NZ (1) NZ764393A (es)
PH (1) PH12020550580A1 (es)
SG (1) SG11202003867SA (es)
WO (1) WO2019099582A1 (es)
ZA (1) ZA202002531B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110248949B (zh) * 2017-01-18 2023-02-17 普林斯匹亚生物制药公司 免疫蛋白酶体抑制剂
EP3710458A1 (en) 2017-11-16 2020-09-23 Principia Biopharma Inc. Immunoproteasome inhibitors
WO2023061445A1 (zh) 2021-10-14 2023-04-20 首药控股(北京)股份有限公司 硼酸衍生物
WO2024006337A1 (en) * 2022-06-30 2024-01-04 Principia Biopharma Inc. Cyclic boronic esters and their uses

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4107288A (en) 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
US4963655A (en) 1988-05-27 1990-10-16 Mayo Foundation For Medical Education And Research Boron analogs of amino acid/peptide protease inhibitors
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
IL111175A0 (en) 1993-10-07 1994-12-29 Du Pont Merck Pharma Electrophilic peptide analogs as inhibitors of trypsin-like serine proteases and pharmaceutical compositions containing them
US6083903A (en) 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
US7576206B2 (en) * 2003-08-14 2009-08-18 Cephalon, Inc. Proteasome inhibitors and methods of using the same
BRPI0507972A (pt) 2004-02-23 2007-07-24 Tufts College composto ,composição farmacêutica , uso de um composto, método para inibição da atividade proteolìtica de uma enzima de clivagem pós prolina e composição farmacêutica embalada
JP6042724B2 (ja) * 2010-03-01 2016-12-14 オニキス セラピューティクス， インク．Ｏｎｙｘ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． イムノプロテアソーム阻害のための化合物
US9688702B2 (en) 2011-12-22 2017-06-27 Ares Trading Alpha-amino boronic acid derivatives, selective immunoproteasome inhibitors
EP3157909B1 (en) 2014-06-20 2021-04-07 Principia Biopharma Inc. Lmp7 inhibitors
AU2015327345B9 (en) * 2014-10-01 2020-06-18 Merck Patent Gmbh Boronic acid derivatives
CN106588965A (zh) * 2015-10-15 2017-04-26 北京大学 脲拟肽硼酸化合物及其药物组合物、制备方法和用途
CN110248949B (zh) * 2017-01-18 2023-02-17 普林斯匹亚生物制药公司 免疫蛋白酶体抑制剂
EP3710458A1 (en) 2017-11-16 2020-09-23 Principia Biopharma Inc. Immunoproteasome inhibitors
US20230133165A1 (en) 2017-11-16 2023-05-04 Principia Biopharma Inc. Immunoproteasome inhibitors

Also Published As

Publication number Publication date
JP2021503471A (ja) 2021-02-12
TW201930264A (zh) 2019-08-01
CO2020007150A2 (es) 2020-06-19
US20200277312A1 (en) 2020-09-03
US11225493B2 (en) 2022-01-18
MX2022012825A (es) 2022-11-07
CA3080949C (en) 2024-04-16
AU2018367515B2 (en) 2023-04-27
CN111491938A (zh) 2020-08-04
MX2020005046A (es) 2020-08-20
SG11202003867SA (en) 2020-05-28
IL274523A (en) 2020-06-30
CA3080949A1 (en) 2019-05-23
CN111491938B (zh) 2024-05-24
JP7277457B2 (ja) 2023-05-19
AU2018367515A1 (en) 2020-05-14
US11827656B2 (en) 2023-11-28
PH12020550580A1 (en) 2021-04-26
KR102625984B1 (ko) 2024-01-18
NZ764393A (en) 2023-11-24
KR20200085868A (ko) 2020-07-15
US20220073538A1 (en) 2022-03-10
BR112020009516A2 (pt) 2020-11-03
ZA202002531B (en) 2023-10-25
IL274523B1 (en) 2023-10-01
WO2019099582A1 (en) 2019-05-23
EP3710458A1 (en) 2020-09-23
IL274523B2 (en) 2024-02-01
MA50906A (fr) 2020-09-23
EA202090900A1 (ru) 2020-10-02

Similar Documents

Publication Publication Date Title
CL2020001244A1 (es) Inhibidores de inmunoproteasoma.
BR112018070677A2 (pt) inibidores de mcl-1 macrocíclicos para o tratamento de câncer
UY36285A (es) Compuestos que inhiben la proteína mcl-1
CL2018000318A1 (es) Compuestos derivados de piridinona, inhibidores de bromodominio; composición farmacéutica que los comprende; y su uso en el tratamiento de enfermedades del cáncer. (solicitud divisional 201600925)
CL2019002204A1 (es) Compuestos inhibidores del vih.
CL2019003086A1 (es) Compuestos de imidazo-piperidina fusionada como inhibidores de jak.
CO2017011172A2 (es) Compuestos de 1-ciano-pirrolidina como inhibidores de usp30
NI201600165A (es) Inhibidores de desmetilasa 1 específica a lisina
BR112017003658A2 (pt) composto, mistura, métodos para tratamento de uma doença e para inibição de uma glicosidase, e, composição farmacêutica.
EA201790078A1 (ru) Ингибиторы mnk и связанные с ними способы
AR108046A1 (es) Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue
CU20160111A7 (es) Compuestos de heterociclilo bicíclico como inhibidores de irak4
BR112018070123A2 (pt) oxiesterós e métodos de uso dos mesmos
UY35243A (es) Inhibidores de fosfatidilinositol 3-cinasa
MX347988B (es) Inhibidores de fosfatidilinositol 3-cinasa.
AR091857A1 (es) INHIBIDORES DE CISTATIONIN-g-LIASA (CSE)
CO2019009423A2 (es) Inhibidores de mnk sustituidos con piperidina y métodos relacionados con los mismos
MX2018001992A (es) Compuestos triciclicos heterociclicos como inhibidores de fosfoinositol 3-quinasa.
UY36875A (es) Composiciones inhibidoras de bromodominios para el tratamiento de diversas enfermedades
PE20180412A1 (es) Compuestos inhibidores de la senalizacion de la via de notch
ECSP22019360A (es) Piperidinil-metil-purinaminas como inhibidores de nsd2 y antineoplásicos
UY37569A (es) Inhibidores del inmunoproteasoma
AR077080A1 (es) Compuestos de 2,3-dihidro-1h-indeno
MX2019006843A (es) Inhibidor de cdk4/6.
UY37837A (es) Nuevos compuestos heterocíclicos como inhibidores de cdk8/19